5-氯-2-甲基-6-苯基-2,3-二氢吡嗪-3-酮 | 51660-08-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 5-氯-2-甲基-6-苯基-2,3-二氢吡嗪-3-酮
• 中文别名: 5-氯-6-苯基-3(2H)-哒嗪酮；5-氯-6-苯基哒嗪-3-醇
• 英文名称: 5-Chloro-3-hydroxy-6-phenylpyridazine
• 英文别名: 5-Chloro-6-phenylpyridazin-3-ol；4-chloro-3-phenyl-1H-pyridazin-6-one
• CAS: 51660-08-3
• 化学式: C₁₀H₇ClN₂O
• mdl: MFCD00832211
• 分子量: 206.631
• InChiKey: ZIBQCQDAFOPHBJ-UHFFFAOYSA-N

物化性质

• 熔点：
  235 °C
• 密度：
  1.35±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  41.5
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2933990090

SDS

Name:	5-Chloro-6-phenylpyridazin-3-ol 97% Material Safety Data Sheet
Synonym:
CAS:	51660-08-3

Section 1 - Chemical Product MSDS Name:5-Chloro-6-phenylpyridazin-3-ol 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
51660-08-3	5-Chloro-6-phenylpyridazin-3-ol	97%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 51660-08-3: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: tan
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 235 - 236 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C10H7ClN2O
Molecular Weight: 207

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents, bases.
Hazardous Decomposition Products:
Hydrogen chloride, chlorine, nitrogen oxides, carbon monoxide, carbon dioxide, acrid smoke and fumes.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 51660-08-3 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
5-Chloro-6-phenylpyridazin-3-ol - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 51660-08-3: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 51660-08-3 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 51660-08-3 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-氯-2-甲基-6-苯基-2,3-二氢吡嗪-3-酮 在 sodium azide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 以78%的产率得到3(2H)-哒嗪酮,5-叠氮-6-苯基-
  参考文献：
  名称：

  Synthesis of Aminopyridazines from Azidopyridazines and Tetrazolo[1,5-b]pyridazines

  摘要：

  叠氮吡哒嗪3、4、24和四唑并[1,5-b]吡哒嗪10、13、28可通过与三苯基膦反应生成膦嗪并随后进行水解（Staudinger反应），转化为相应的氨基吡哒嗪。

  DOI：

  10.1055/s-1989-27352
• 作为产物：
  描述：

  苯 在 aluminum (III) chloride 、 一水合肼 作用下， 以 乙醇 为溶剂， 反应 27.0h， 生成 5-氯-2-甲基-6-苯基-2,3-二氢吡嗪-3-酮
  参考文献：
  名称：

  脲基哒嗪酮衍生物：对 STAT3 抑制的结构和构象特性的洞察

  摘要：

  考虑到我们小组先前研究的几种脲基-恶二唑衍生物的构效关系，设计了三种新的脲基-哒嗪酮衍生物，它们在结构上与已知的 STAT3 抑制剂 AVS-0288 相关。它们的合成首先通过合适的 5-氨基哒嗪酮中间体（6a 和 6b）尝试合成，其分子结构通过 6a 的 X 射线衍射数据得到证实。胺官能化不成功，因此，设计了替代方法。双荧光素酶和基于 AlphaScreen 的测定被用来测试它们的活性。在建模研究的基础上对获得的数据进行了合理化，该研究将我们的注意力集中在脲基部分的几何偏好上。计算结果似乎表明 1,2,

  DOI：

  10.1002/ejoc.201500599

文献信息

• Pyridazines.<b>XV</b>. Synthesis of 6-aryl-5-amino-3(2<i>H</i>)-pyridazinones as potential platelet aggregation inhibitors
  作者：Isabel Estevez、Enrique Raviña、Eddy Sotelo

  DOI：10.1002/jhet.5570350634

  日期：1998.11

  Several 3(2H)-pyridazinones with amino groups at the 5-position of the pyridazine nucleus have been prepared. The 6-aryl-5-halo-3(2H)-pyridazinones obtained from mucochloric and mucobromic acid lead to the corresponding 5-alkylamino-3(2H)-pyridazinones, which were tested as platelet aggregation inhibitors.

  已经制备了几个在哒嗪核的5-位具有氨基的3（2 H）-哒嗪酮。从粘氯酸和粘溴酸得到的6-芳基-5-卤代-3（2 H）-哒嗪酮导致相应的5-烷基氨基-3（2 H）-哒嗪酮，其被测试为血小板聚集抑制剂。
• Synthesis of Aminopyridazines from Azidopyridazines and Tetrazolo[1,5-<i>b</i>]pyridazines
  作者：Th. Kappe、A. Pfaffenschlager、W. Stadlbauer

  DOI：10.1055/s-1989-27352

  日期：——

  Azidopyridazines 3, 4, 24 and tetrazolo[1,5-b]pyridazines 10, 13, 28 can be converted to the corresponding aminopyridazines, by reaction with triphenylphosphine via phosphazenes and subsequent hydrolysis (Staudinger reaction).

  叠氮吡哒嗪3、4、24和四唑并[1,5-b]吡哒嗪10、13、28可通过与三苯基膦反应生成膦嗪并随后进行水解（Staudinger反应），转化为相应的氨基吡哒嗪。
• [EN] PYRROLIDINYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS<br/>[FR] COMPOSÉS DE N-PYRROLIDINYLE URÉE, THIO-URÉE,GUANIDINE ET CYANOGUANIDINE EN TANT QU'INHIBITEURS DE LA KINASE TRKA
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2014078378A1

  公开（公告）日：2014-05-22

  Compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts, or solvates or prodrugs thereof, where R1, R2, Ra, Rb, Rc, Rd, X, Ring B, and Ring C are as defined herein, and wherein Ring B moiety and the NH-C(=X)-NH moiety are in the trans configuration, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.

  公式（I）的化合物：或其立体异构体、互变异构体、药用可接受的盐、溶剂合物或前药，其中R1、R2、Ra、Rb、Rc、Rd、X、环B和环C的定义如本文所述，其中环B基团和NH-C(=X)-NH基团处于反式构型，是TrkA激酶的抑制剂，并且可用于治疗可以用TrkA激酶抑制剂治疗的疾病，如疼痛、癌症、炎症/炎症性疾病、神经退行性疾病、某些传染病、干燥综合症、子宫内膜异位症、糖尿病周围神经病变、前列腺炎和盆腔疼痛综合征。
• Pyridazines. Part XXIX: synthesis and platelet aggregation inhibition activity of 5-substituted-6-phenyl-3(2H)-pyridazinones. Novel aspects of their biological actions
  作者：Eddy Sotelo、Nuria Fraiz、Matilde Yáñez、Vicente Terrades、Reyes Laguna、Ernesto Cano、Enrique Raviña

  DOI：10.1016/s0968-0896(02)00146-3

  日期：2002.9

  series of 6-phenyl-3(2H)-pyridazinones with a diverse range of substituents in the 5-position have been prepared and evaluated in the search for new antiplatelet agents. A significant dependence of the substituent on the inhibitory effect has been observed. The pharmacological study of these compounds confirms that modification of the chemical group at position 5 of the 6-phenyl-3(2H)-pyridazinone system

  已经制备了一系列5-位具有5-取代基范围的6-苯基-3（2H）-哒嗪酮，并在寻找新的抗血小板药时对其进行了评估。已经观察到取代基对抑制作用的显着依赖性。这些化合物的药理研究证实，6-苯基-3（2H）-哒嗪酮系统第5位的化学基团的修饰既影响抗血小板活性的变化，又影响作用机理。
• [EN] PYRIDONE AND PYRIDAZONE ANALOGUES AS GPR119 MODULATORS<br/>[FR] ANALOGUES DE PYRIDONE ET DE PYRIDAZONE COMME MODULATEURS DE GPR119
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2010009183A1

  公开（公告）日：2010-01-21

  Novel compounds of structure Formula (I) or an enantiomer, a diastereomer, or a pharmaceutically acceptable salt thereof, wherein Z, R1, R2, R21, T1, T2, T3 and T4 are defined herein, are provided which are GPR119 G protein-coupled receptor modulators. GPR119 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring GPR119 G protein-coupled receptor modulator therapy. Thus, the disclosure also concerns compositions comprising these novel compounds and methods of treating diseases or conditions related to the activity of the GPR119 G protein-coupled receptor by using any of these novel compounds or a composition comprising any of such novel compounds.

  提供结构式（I）或其对映体、顺反异构体或药用可接受盐的新化合物，其中Z、R1、R2、R21、T1、T2、T3和T4在此定义，这些化合物是GPR119 G蛋白偶联受体调节剂。 GPR119 G蛋白偶联受体调节剂在治疗、预防或减缓需要GPR119 G蛋白偶联受体调节剂治疗的疾病方面是有用的。因此，该公开还涉及包含这些新化合物的组合物和使用任何这些新化合物或包含任何这种新化合物的组合物治疗与GPR119 G蛋白偶联受体活性相关的疾病或症状的方法。